What is Cumberland Pharmaceuticals's talicia — revenue?

Cumberland Pharmaceuticals (CPIX) reported talicia — revenue of $1.92M in Q1 2026.

What does talicia — revenue mean?

This metric represents the total net sales generated from the commercialization of the Talicia product line. It serves as a key indicator of market adoption and revenue growth for the company's specialty pharmaceutical portfolio within the gastroenterology segment. Tracking these revenues helps investors evaluate the product's contribution to overall top-line performance and its lifecycle stage in the competitive pharmaceutical market.

Cumberland Pharmaceuticals CPIX Talicia — Revenue

Other product segments

Kristalose

$3.12M-28.7%

Sancuso

$2.93M+29.8%

Vibativ

$2.12M-29.4%

Caldolor

$896.71K-34.7%

Other revenue

$168.85K-94.6%

Acetadote

$66.67K+65.8%

Similar metrics at other companies

LLYTaltz — Revenue

$733M-3.8%

JNJTALVEY — Sales to customers (Note 9)

$152M+76.7%

GILDTecartus — Total revenues

$75M-3.8%

INCYTABRECTA — Total revenues

$6M-6.3%

AMGNTEPEZZA — Total revenues

$490M+28.6%

JNJTecvayli — Sales to customers (Note 9)

$202M+33.8%

Other financials

Income statement

See full

Revenue$9.1M-22.0%

Gross profit$7.2M-30.0%

Operating income-$3.1M-342%

Net income-$3.3M-362%

EPS (diluted)-$0.22-375%

Balance sheet

See full

Cash & equivalents$11.0M-27.1%

Total debt$4.8M-7.1%

Total equity$21.6M-24.5%

Total assets$71.0M+1.5%

Cash flow

See full

Operating cash flow$387.0K-90.1%

CapEx--100%

Free cash flow$387.0K-89.9%

Valuation

See full

Market cap$97.09M+142%

Enterprise value$90.91M+212%

P/S2.3×+1.4×

Profitability

See full

Gross margin82.9%-1.4pp

Operating margin-17.2%-125pp

Net margin-17.6%-103pp

FCF margin3.3%—

Returns & leverage

See full

Return on equity-29.4%-86.3pp

Debt / equity0.2×0.0×

Current ratio1×-0.3×

Where this comes from

Reported directly by Cumberland Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Cumberland Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cumberland Pharmaceuticals's talicia — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Cumberland Pharmaceuticals's talicia — revenue?: Cumberland Pharmaceuticals (CPIX) reported talicia — revenue of $1.92M in Q1 2026.
What does talicia — revenue mean?: This metric represents the total net sales generated from the commercialization of the Talicia product line. It serves as a key indicator of market adoption and revenue growth for the company's specialty pharmaceutical portfolio within the gastroenterology segment. Tracking these revenues helps investors evaluate the product's contribution to overall top-line performance and its lifecycle stage in the competitive pharmaceutical market.